Today, Invent Medic publishes a new issue of the company’s newsletter aimed at shareholders, investors and other interested parties.
In this issue, CEO Karin Bryder informs that ongoing procurement processes and negotiations with Swedish healthcare regions continued during the spring, with Kronoberg and Blekinge becoming the sixth and seventh region to be able to offer Efemia to its patients on October 1. She also comments on early signs indicating that the European healthcare systems are initiating a normalisation phase, and informs that the company’s preparatory work before applying for market approval of Efemia in the United States has continued as planned.
To read the newsletter, and subscribe for upcoming issues, follow this link:
The newsletter is published in Swedish and English, with a flexible publishing frequency based on Invent Medic’s news flow. It is produced together with the company’s IR communication partner Honeybadger, http://www.honeybadger.se. Invent Medic encourages feedback and requests on topics for upcoming issues of the newsletter.